Compare CLGN & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLGN | HKPD |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Israel | Hong Kong |
| Employees | N/A | 27 |
| Industry | Industrial Specialties | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.9M |
| IPO Year | 2015 | N/A |
| Metric | CLGN | HKPD |
|---|---|---|
| Price | $0.33 | $0.43 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 39.3K | ★ 392.7K |
| Earning Date | 05-27-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $240.45 | N/A |
| Revenue Next Year | $38.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.32 |
| 52 Week High | $3.23 | $2.58 |
| Indicator | CLGN | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 29.38 | 38.04 |
| Support Level | $0.27 | $0.37 |
| Resistance Level | $0.45 | $0.71 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.11 | 42.66 |
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.